Novartis AG vs Xpeng Inc - ADR — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Xpeng Inc - ADR trades at $13.35 (market cap $12.96B). The key difference: Novartis AG is far larger — about 22.4× Xpeng Inc - ADR's market cap, and Novartis AG pays a 3.17% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| NVS | XPEV | |
|---|---|---|
Market Cap | $290.25B | $12.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $28.07 |
52-Week Low | $113.50 | $12.09 |
Enterprise Value | $330.27B | $15.07B |
Dividend Yield | 3.17% | — |
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →